The mechanism and clinical application of farnesyl diphosphate farnesyltransferase 1 in cancer metabolism
Open Access
- 6 May 2024
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 719, 150046
Abstract
No abstract availableKeywords
This publication has 58 references indexed in Scilit:
- FDFT1 repression by piR-39980 prevents oncogenesis by regulating proliferation and apoptosis through hypoxia in tongue squamous cell carcinomaLife Sciences, 2023
- Genome-wide profiling of dysregulated piRNAs and their target genes implicated in oncogenicity of tongue squamous cell carcinomaGene, 2022
- Identification of FDFT1 as a potential biomarker associated with ferroptosis in ccRCCCancer Medicine, 2022
- Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1Biochemical and Biophysical Research Communications, 2021
- 20(S)-Rg3 upregulates FDFT1 via reducing miR-4425 to inhibit ovarian cancer progressionArchives of Biochemistry and Biophysics, 2020
- Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLMMolecular Therapy-Oncolytics, 2019
- An Overview of Cholesterol Homeostasis2017
- Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progressionCellular and Molecular Life Sciences, 2015
- From cancer metabolism to new biomarkers and drug targetsBiotechnology Advances, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011